Mouse Monoclonal CSF3 Antibody

+ +

•  

   
     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

•  

   
     Immunofluorescence analysis of A549 cells using CSF3 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

•  

   
     Immunofluorescence analysis of Hela cells using CSF3 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

•  

   
     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using CSF3 mouse mAb with DAB staining.    

**Background of CSF3 Antibodies**

CSF3 (colony-stimulating factor 3), also known as granulocyte colony-stimulating factor (G-CSF), is a glycoprotein critical for stimulating neutrophil production, differentiation, and survival. It binds to the CSF3 receptor (CSF3R) on hematopoietic cells, activating signaling pathways like JAK/STAT and MAPK to regulate immune responses and hematopoiesis.

Therapeutic CSF3 analogs (e.g., filgrastim, pegfilgrastim) are widely used to combat chemotherapy-induced neutropenia or enhance neutrophil recovery post-transplant. However, prolonged use can trigger anti-CSF3 antibodies, which may neutralize drug efficacy or, rarely, cause immune-mediated adverse effects. These antibodies are classified as anti-drug antibodies (ADAs) and are monitored in clinical settings to optimize treatment safety.

In research, anti-CSF3 antibodies serve as tools to study CSF3R signaling or block CSF3 activity in disease models. For instance, CSF3 overexpression is linked to chronic inflammation and cancer progression; neutralizing antibodies are explored to inhibit tumor growth or metastasis. Additionally, naturally occurring autoantibodies against CSF3 have been reported in autoimmune disorders, though their clinical significance remains under investigation.

Overall, CSF3 antibodies hold dual relevance: as therapeutic targets to modulate neutrophil dynamics and as biomarkers to assess immunogenicity during CSF3-based therapies. Their study bridges translational immunology and oncology, offering insights into immune regulation and disease mechanisms.